Multidrug resistance phenotype by treatment arm
| . | HDAC/DNR, n = 40 . | HDAC/DNR + CsA, n = 37 . | ||
|---|---|---|---|---|
| No. positive/no. patients . | Percentage . | No. positive/no. patients . | Percentage . | |
| Duplicate Ph | 5/37 | 14 | 5/36 | 14 |
| Pgp* | 20/36 | 56 | 22/36 | 61 |
| CsA-inhibited DiOC2 efflux† | 22/36 | 61 | 21/36 | 58 |
| MRP1* | 8/36 | 22 | 5/36 | 14 |
| LRP* | 23/35 | 66 | 28/36 | 78 |
| . | HDAC/DNR, n = 40 . | HDAC/DNR + CsA, n = 37 . | ||
|---|---|---|---|---|
| No. positive/no. patients . | Percentage . | No. positive/no. patients . | Percentage . | |
| Duplicate Ph | 5/37 | 14 | 5/36 | 14 |
| Pgp* | 20/36 | 56 | 22/36 | 61 |
| CsA-inhibited DiOC2 efflux† | 22/36 | 61 | 21/36 | 58 |
| MRP1* | 8/36 | 22 | 5/36 | 14 |
| LRP* | 23/35 | 66 | 28/36 | 78 |